Dacomitinib PF-00299804 vs Pyrotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline
Dacomitinib PF-00299804
Rights held by Pfizer; US product discontinued
NCT01774721 · Phase 3 · completed
The 452 participants were randomly assigned to dacomitinib or the active comparator gefitinib, but the study was open-label rather than double-blinded. The hard clinical primary endpoint, independently assessed progression-free survival, was met in favor of dacomitinib, but the lack of blinding limits the strength of the evidence.
Next expected readout: April 2027 · NCT04946968 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11) (met)
Result source: NCT01774721
Pyrotinib
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
NCT04447118 · Phase 3 · completed
The study randomly assigned 151 participants to pyrotinib or active treatment with docetaxel, with the primary endpoint assessed by an independent committee blinded to treatment assignment. Because results for the progression-free survival comparison have not been posted, the trial provides limited evidence at this time despite its randomized design.
Next expected readout: December 2026 · NCT05482568 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dacomitinib PF-00299804 | Pyrotinib |
|---|---|---|
| PFS, median | 14.7 vs 9.2vs GefitinibNCT0177472111 other results
| —Not posted · NCT04447118 |
| OS, median | 6.8 vs 6.3+0.5 vs placeboNCT010000258 other results
| —Not posted · NCT04447118 |
| ORR | 7.1% vs 1.3%+5.8 vs placeboNCT010000255 other results
| —Not posted · NCT04447118 |
| Duration of response, median | 9.2 vs 10.1vs ErlotinibNCT013605548 other results
| —Not posted · NCT04447118 |
PFS, median
- Dacomitinib PF-00299804
- 14.7 vs 9.2vs GefitinibNCT01774721
11 other results
- 2.6 vs 2.5 NCT01360554
- 2.6 vs 2.5 NCT01360554
- 2.7 vs 1.6 NCT01000025
- 16.6 vs 11 NCT01774721
- 1.9 vs 1.9 NCT01360554
- 1.9 vs 1.9 NCT01360554
- 2.9 vs 1.9 NCT00769067
- 11.5 NCT00818441
- 2.3 NCT01858389
- 1.6 NCT01858389
- 2.6 NCT00818441
- Pyrotinib
- —Not posted · NCT04447118
OS, median
- Dacomitinib PF-00299804
- 6.8 vs 6.3+0.5 vs placeboNCT01000025
8 other results
- 7 vs 5.2 NCT01000025
- 7.2 vs 7.5 NCT01000025
- 34.1 vs 27 NCT01774721
- 7.9 vs 8.3 NCT01360554
- 8.1 vs 8.5 NCT01360554
- 9.6 vs 7.5 NCT00769067
- 29.5 NCT00818441
- 9.3 NCT00818441
- Pyrotinib
- —Not posted · NCT04447118
ORR
- Dacomitinib PF-00299804
- 7.1% vs 1.3%+5.8 vs placeboNCT01000025
5 other results
- 74.9% vs 71.6% NCT01774721
- 75.3% vs 70.2% NCT01774721
- 6.3% NCT01858389
- 17% vs 5.3% NCT00769067
- 50.5% NCT04511533
- Pyrotinib
- —Not posted · NCT04447118
Duration of response, median
- Dacomitinib PF-00299804
- 9.2 vs 10.1vs ErlotinibNCT01360554
8 other results
- 10.4 vs 9.2 NCT01360554
- 16.6 vs 9.3 NCT00769067
- 11.1 NCT04511533
- 12.9 NCT00818441
- 12.4 NCT00818441
- 2.8 NCT01858389
- 10.4 NCT00548093
- 2.8 NCT00548093
- Pyrotinib
- —Not posted · NCT04447118
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Pyrotinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dacomitinib PF-00299804: 4 of 4 rows · Pyrotinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dacomitinib PF-00299804 |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more resultsn/a: no completion milestone NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 — NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 79.2% NCT04511533 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT02382796 · Phase 2 · registry result, not featured evidence n/a: no completion milestone45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence n/a: no completion milestone45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 50%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 36.4%45 mg + 100 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 0%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 43.3%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 48%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneDacomitinib: Cohort A NCT00818441 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneDacomitinib: Cohort B NCT00818441 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT00769067 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePF-00299804 (Adenocarcinoma Histol NCT00548093 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePF-00299804 (Non-adenocarcinoma Hi NCT00548093 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more results— NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 — NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 — NCT04511533 · Phase 4 · registry result, not featured evidence — NCT02382796 · Phase 2 · registry result, not featured evidence 18.8%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 4%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg + 100 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence 0%Dacomitinib: Cohort A NCT00818441 · Phase 2 · registry result, not featured evidence 3.3%Dacomitinib: Cohort B NCT00818441 · Phase 2 · registry result, not featured evidence — NCT00769067 · Phase 2 · registry result, not featured evidence —PF-00299804 (Adenocarcinoma Histol NCT00548093 · Phase 2 · registry result, not featured evidence —PF-00299804 (Non-adenocarcinoma Hi NCT00548093 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 30.4%a NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more results40.8% NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 40% NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 15.8% NCT04511533 · Phase 4 · registry result, not featured evidence 28.6% NCT02382796 · Phase 2 · registry result, not featured evidence 43.8%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 36.4%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 37.9%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 40.9%45 mg + 100 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 42.9%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 32.8%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 24%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence 32.6%Dacomitinib: Cohort A NCT00818441 · Phase 2 · registry result, not featured evidence 30%Dacomitinib: Cohort B NCT00818441 · Phase 2 · registry result, not featured evidence 36.6% NCT00769067 · Phase 2 · registry result, not featured evidence 18%PF-00299804 (Adenocarcinoma Histol NCT00548093 · Phase 2 · registry result, not featured evidence 37.5%PF-00299804 (Non-adenocarcinoma Hi NCT00548093 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a diarrhoea 87.7% paronychia 61.7% dermatitis acneiform 49.3% NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more resultsdiarrhoea 73.9% rash 50% decreased appetite 31.7% NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 diarrhea 79.7% (placebo 19.7%) rash acneiform 59.3% (placebo 10%) dyspnea 57.9% (placebo 55.2%) NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 diarrhoea 51.5% rash 42.6% weight decreased 34.7% NCT04511533 · Phase 4 · registry result, not featured evidence contusion 28.6% diarrhoea 28.6% dry skin 28.6% NCT02382796 · Phase 2 · registry result, not featured evidence 45/60 mg diarrhoea 87.5% rash 50% dry skin 43.8% NCT01858389 · Phase 2 · registry result, not featured evidence 45/60 mg diarrhoea 72.7% rash 54.5% nausea 40.9% NCT01858389 · Phase 2 · registry result, not featured evidence 45 mg diarrhoea 81.8% nausea 42.4% rash 42.4% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg + 100 mg diarrhoea 78.8% nausea 47% rash 43.9% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg diarrhoea 100% rash 71.4% chills 57.1% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg diarrhoea 80.6% decreased appetite 37.3% rash 37.3% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg diarrhoea 92% dermatitis acneiform 72% pruritus 68% NCT01465802 · Phase 2 · registry result, not featured evidence diarrhoea 95.5% dermatitis acneiform 76.4% dry skin 43.8% NCT00818441 · Phase 2 · registry result, not featured evidence diarrhoea 93.3% dermatitis acneiform 73.3% fatigue 56.7% NCT00818441 · Phase 2 · registry result, not featured evidence diarrhoea 72% dermatitis acneiform 64.5% decreased appetite 29% NCT00769067 · Phase 2 · registry result, not featured evidence diarrhoea 88% dermatitis acneiform 66% fatigue 62% NCT00548093 · Phase 2 · registry result, not featured evidence diarrhoea 81.3% dermatitis acneiform 75% dry skin 43.8% NCT00548093 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 14 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dacomitinib PF-00299804
show 7 more results
show 6 more results
show 1 more result
show 1 more result
show 3 more results
show 2 more results
show 1 more result
show 5 more results
+ 25 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dacomitinib PF-00299804's landscape · Pyrotinib's landscape